CardioExchange Archive

March 24th, 2011

Study Finds Pioglitazone Prevents Progression To Diabetes

Larry Husten, PHD

Pioglitazone significantly reduces the development of type 2 diabetes in people with impaired glucose tolerance, according to the results of the ACT NOW study published in the New England Journal of Medicine. Ralph DeFronzo and colleagues randomized 602 patients with impaired glucose tolerance to pioglitazone or placebo. During a median followup of  2.4 years, diabetes developed […]

---

March 10th, 2011

Olmesartan Helps Prevent Microalbuminuria, But a Troubling Question Persists

Larry Husten, PHD

Olmesartan can help prevent progression to microalbuminuria in type 2 diabetics, according to results of the ROADMAP (Randomized Olmesartan and Diabetes Microalbuminuria Prevention) trial published in the New England Journal of Medicine. But the positive result was partially offset by the troubling finding of a small but significant increase in fatal cardiovascular events. Type 2 diabetics […]

---

March 7th, 2011

Meta-Analysis Finds Mediterranean Diet Helps Fight Metabolic Syndrome

Larry Husten, PHD

The Mediterranean diet may be a potent weapon in the battle to halt the growth of metabolic syndrome (MS), a new meta-analysis suggests. Christina-Maria Kastorini and colleagues performed a meta-analysis on 50 studies including nearly 535,000 participants. In their paper in the Journal of the American College of Cardiology, they report that adherence to the Mediterranean […]

---

March 3rd, 2011

5-Year Followup of ACCORD: Still No Support For Intensive Glucose Lowering

Larry Husten, PHD

Long-term followup of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial has once again failed to support routine intensive glucose lowering in high-risk type 2 diabetics. In 2008, as reported in the New England Journal of Medicine, the intensive glucose-lowering regimen (target glycated hemoglobin level of <6%) was terminated early after an increase in mortality was […]

---

October 8th, 2010

Analysis of ADVANCE Explores Role of Hypoglycemia

Larry Husten, PHD

A new analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) trial sheds light on the role of hypoglycemia in recent trials of glucose control. In a paper in the New England Journal of Medicine, the ADVANCE investigators report that 2.1% of 11,140 patients with type 2 diabetes […]

---